Ashland(US:ASH) ZACKSยท2024-08-07 00:00Core Insights - For the quarter ended June 2024, Ashland reported revenue of $544 million, a decrease of 0.4% year-over-year, with EPS at $1.49 compared to $1.23 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $569.02 million by 4.40%, while the EPS exceeded the consensus estimate of $1.47 by 1.36% [1] Revenue Performance - Revenue from Intermediates was $36 million, below the average estimate of $40.87 million, representing a year-over-year decline of 16.3% [3] - Revenue from Specialty Additives was $150 million, slightly below the average estimate of $154.91 million, with a year-over-year decrease of 1.3% [4] - Revenue from Personal Care reached $175 million, surpassing the average estimate of $162.63 million, showing a year-over-year increase of 19.9% [5] - Revenue from Life Sciences was $195 million, below the estimated $220.99 million, reflecting an 11% decline year-over-year [6] Adjusted EBITDA Performance - Adjusted EBITDA for Life Sciences was $59 million, compared to the average estimate of $67.79 million [7] - Adjusted EBITDA for Intermediates was $9 million, below the average estimate of $12.20 million [8] - Adjusted EBITDA for Specialty Additives was $38 million, exceeding the average estimate of $33.68 million [9] - Adjusted EBITDA for Personal Care was $51 million, above the average estimate of $46.67 million [10] Stock Performance - Ashland's shares have returned -3.9% over the past month, compared to a -6.7% change in the Zacks S&P 500 composite [11] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [11]